Foresite Capital KURA Position
Exited10-Fund ConvergenceForesite Capital exited their position in Kura Oncology, Inc. (KURA) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
KURA is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 16.3% of float with 8.3 days to cover, indicating significant bearish positioning against the stock.
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Full company profile →Short Interest
16.3%
8.3 days to cover
Foresite Capital KURA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -816,882 | $0 |
| Q2 2025 | Decreased | 816,882 | -295,000 | $4.7M |
| Q1 2025 | Decreased | 1,111,882 | -615,000 | $7.3M |
| Q4 2024 | Decreased | 1,726,882 | -123,065 | $15.0B |
| Q3 2024 | Held | 1,849,947 | — | $36.1M |
| Q2 2024 | Held | 1,849,947 | — | $38.1M |
| Q1 2024 | Held | 1,849,947 | — | $39.5M |
| Q4 2023 | Held | 1,849,947 | — | $26.6M |
| Q3 2023 | Held | 1,849,947 | — | $16.9M |
| Q2 2023 | Held | 1,849,947 | — | $19.6M |
| Q1 2023 | New | 1,849,947 | +1,849,947 | $22.6M |
Frequently Asked Questions
Does Foresite Capital own KURA?
No. Foresite Capital exited their position in Kura Oncology, Inc. (KURA) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own KURA?
10 specialist biotech hedge funds currently hold KURA, including EcoR1 Capital, Deerfield Management, BVF Partners and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Foresite Capital first buy KURA?
Foresite Capital's position in KURA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Foresite Capital's KURA position increasing or decreasing?
Foresite Capital completely exited their KURA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KURACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Foresite CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →